Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 167

1.

A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.

Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S.

Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16685-9.

2.

Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease.

Cho SR, Benraiss A, Chmielnicki E, Samdani A, Economides A, Goldman SA.

J Clin Invest. 2007 Oct;117(10):2889-902.

3.

Histone deacetylase inhibitors selectively suppress expression of HDAC7.

Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani RB, Marks PA.

Mol Cancer Ther. 2007 Sep;6(9):2525-34.

4.

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.

Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M.

Biochem J. 2008 Jan 15;409(2):581-9.

PMID:
17868033
5.

Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood.

Runne H, Kuhn A, Wild EJ, Pratyaksha W, Kristiansen M, Isaacs JD, Régulier E, Delorenzi M, Tabrizi SJ, Luthi-Carter R.

Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14424-9.

6.

Nortriptyline delays disease onset in models of chronic neurodegeneration.

Wang H, Guan Y, Wang X, Smith K, Cormier K, Zhu S, Stavrovskaya IG, Huo C, Ferrante RJ, Kristal BS, Friedlander RM.

Eur J Neurosci. 2007 Aug;26(3):633-41.

PMID:
17686041
8.

Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease.

Zuccato C, Belyaev N, Conforti P, Ooi L, Tartari M, Papadimou E, MacDonald M, Fossale E, Zeitlin S, Buckley N, Cattaneo E.

J Neurosci. 2007 Jun 27;27(26):6972-83.

9.

The commonality of protein interaction networks determined in neurodegenerative disorders (NDDs).

Limviphuvadh V, Tanaka S, Goto S, Ueda K, Kanehisa M.

Bioinformatics. 2007 Aug 15;23(16):2129-38.

PMID:
17553855
10.

Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.

Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RL, Olson JM, Bates GP, Jones L, Luthi-Carter R.

Hum Mol Genet. 2007 Aug 1;16(15):1845-61.

PMID:
17519223
11.

Alzforum and SWAN: the present and future of scientific web communities.

Clark T, Kinoshita J.

Brief Bioinform. 2007 May;8(3):163-71.

PMID:
17510163
12.

Huntington's disease: pathological mechanisms and therapeutic strategies.

Ramaswamy S, Shannon KM, Kordower JH.

Cell Transplant. 2007;16(3):301-12. Review.

PMID:
17503740
13.

Huntingtin interacting proteins are genetic modifiers of neurodegeneration.

Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J, Hurlburt A, Cha GH, Ukani L, Chepanoske CL, Zhen Y, Sahasrabudhe S, Olson J, Kurschner C, Ellerby LM, Peltier JM, Botas J, Hughes RE.

PLoS Genet. 2007 May 11;3(5):e82.

14.

Transcriptional signatures in Huntington's disease.

Cha JH.

Prog Neurobiol. 2007 Nov;83(4):228-48. Review.

15.

Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease.

Lynch G, Kramar EA, Rex CS, Jia Y, Chappas D, Gall CM, Simmons DA.

J Neurosci. 2007 Apr 18;27(16):4424-34.

16.

Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models.

Sadri-Vakili G, Bouzou B, Benn CL, Kim MO, Chawla P, Overland RP, Glajch KE, Xia E, Qiu Z, Hersch SM, Clark TW, Yohrling GJ, Cha JH.

Hum Mol Genet. 2007 Jun 1;16(11):1293-306.

PMID:
17409194
17.

Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation.

Dompierre JP, Godin JD, Charrin BC, Cordelières FP, King SJ, Humbert S, Saudou F.

J Neurosci. 2007 Mar 28;27(13):3571-83.

18.

Role of brain-derived neurotrophic factor in Huntington's disease.

Zuccato C, Cattaneo E.

Prog Neurobiol. 2007 Apr;81(5-6):294-330. Review.

PMID:
17379385
19.

Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.

Zourlidou A, Gidalevitz T, Kristiansen M, Landles C, Woodman B, Wells DJ, Latchman DS, de Belleroche J, Tabrizi SJ, Morimoto RI, Bates GP.

Hum Mol Genet. 2007 May 1;16(9):1078-90.

PMID:
17360721
20.

Abnormal cortical synaptic plasticity in a mouse model of Huntington's disease.

Cummings DM, Milnerwood AJ, Dallérac GM, Vatsavayai SC, Hirst MC, Murphy KP.

Brain Res Bull. 2007 Apr 30;72(2-3):103-7.

PMID:
17352933

Supplemental Content

Support Center